Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

N/AActive Not RecruitingNCT06048185

Nanoscope Therapeutics Inc.6 enrolled

Overview

The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.

This study is designed to follow subjects with Stargardt Disease (SD) previously enrolled in study NTXMCO-004 (STARLIGHT, NCT05417126). In that study, all 6 enrolled subjects received MCO-010, an ambient light-activated, Multi-Characteristic Opsin (MCO) transgene in an adeno-associated virus serotype 2 (AAV2) vector via intravitreal injection (IVT). MCO-010 has the potential to restore vision irrespective of the underlying gene mutation, and because it is directed at bipolar retinal cells, intact photoreceptors are not required. Further details on MCO-010 and the underlying disease under investigation are included in the protocol for STARLIGHT and are not repeated herein

Study Type

OBSERVATIONAL

Enrollment

Conditions

Stargardt Disease

Interventions

Gene Therapy Product-MCO-010BIOLOGICAL

The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects are eligible to be included in the study only if all of the following criteria apply: 1. Previously enrolled in study NTXMCO-004 study 2. Able to comprehend and give informed consent. 3. Able to comply with testing and all protocol tests. 4. Agree to participate for the full 4-year study duration to the best of their ability and barring any unforeseen circumstances. Exclusion Criteria: * Not applicable. Subjects will be included in this study and will be consented after completion of all assessments at the Week 48 visit for the STARLIGHT study

Locations (2)

Nanocope Clnical Site

Miami, Florida, United States

Nanoscope Clinical Site

McAllen, Texas, United States

Outcomes

Primary Outcomes

Assessment of the long-term safety profile of a single intravitreal injection of MCO-010

Assessment of incidences, nature, and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs); intraocular inflammation graded through ocular exam; clinical examination, and intraocular pressure.

Time frame: 204 weeks

Secondary Outcomes

Evaluation of the long-term effects on visual acuity of a single intravitreal injection of MCO-010; 1.2E11 gc/eye

Change from baseline in BCVA over time in the study eye and fellow eye

Time frame: 204 weeks

Exploration of the long-term impact of MCO-010 on retinal anatomy

Assessment of fundus photography and optical coherence tomography (OCT) outcomes over time

Time frame: 204 weeks

Assessment of the long-term durability of MCO-010 induced on gene reporter expression

Change from baseline of fundus fluorescence intensity of reporter (mCherry) over time in the study eye and fellow eye

Time frame: 204 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.